ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2989

Risk of Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort

Medha Barbhaiya1, Candace H. Feldman1, Sarah K. Chen2, Hongshu Guan3, Tzu-Chieh Lin1, Michael A. Fischer4, Daniel H. Solomon5, Brendan M. Everett6 and Karen H. Costenbader1, 1Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Beth Israel Deaconess Medical Center, Boston, MA, 3Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 5Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 6Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Heart disease and systemic lupus erythematosus (SLE), SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: 2016 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Cardiovascular disease (CVD) risk is elevated in SLE patients compared to non-SLE patients.  However, how CVD rates differ in SLE patients compared with other chronic disease states, in particular diabetes mellitus (DM), has not been examined. To provide insights for clinicians seeking to understand the magnitude of CVD risk in SLE patients, we compared their risk to that of patients with DM, a known CVD risk factor. We examined annual rates and relative risks of CVD events (acute myocardial infarction [MI], stroke, and combined MI or stroke) in a nationwide cohort of US Medicaid recipients with either SLE or DM.

Methods : We utilized Medicaid Analytic eXtract (MAX) data, containing billing claims for Medicaid patients from the 29 most populated US states, 2007-10. We identified adults aged ≥18-65 with prevalent SLE or DM (≥3 ICD-9 codes for SLE or DM, each separated by ≥30 days) and >6 months of enrollment prior to 3rd code (index date). We performed 1: 2 matching (SLE: DM) based on age (month/year), sex, and index date. Sociodemographic data (including age, sex, race/ethnicity, calendar year, US region, zip code-level socioeconomic status) and medical/cardiac comorbidities were collected during the baseline period (6 months prior to and including index date). ICD-9, CPT, and DRG codes were used to identify outcomes. Outcomes were assessed from index date, including acute MI, stroke, and combined MI or stroke. Subjects were followed to first CVD event, death, Medicaid disenrollment, or end of follow-up. We used Cox sub-distribution regression models to calculate hazard ratios (HRSD) for CVD events, accounting for the competing risk of death and adjusting for sociodemographics and medical/cardiac comorbidities (Table).

Results : 32,089 prevalent SLE patients were matched to 64,178 prevalent DM patients. In both cohorts, 92.8% were female and mean age was 41.3 (±12.1) years. There were more Blacks (41.1 vs. 30.5%) and fewer Whites (36.3 vs 45.1%) in the SLE vs. DM cohort. Mean follow-up was 1.67 (±1.03) years for SLE patients and 1.79 (±1.07) years for DM patients. Baseline CVD risk factors were more prevalent among DM vs. SLE patients: hypertension (38.0 vs. 33.7%), hyperlipidemia (22.5 vs. 10.6%), and obesity (11 vs. 4.5%). In the SLE cohort in particular, the incidence of stroke was higher than that of MI (Table).  Annual rates and adjusted risks of MI were similar in the two cohorts (multivariable-adjusted HRSD 1.01 [95% CI 0.84-1.22] for SLE vs. DM). By contrast, stroke rates were higher among SLE vs. DM patients and the multivariable-adjusted HRSD for stroke was 1.38 (95%CI 1.20-1.60). 

Conclusion : Despite a lower prevalence of many traditional CVD risk factors compared to age- and sex-matched DM patients, SLE patients had similar adjusted risks of MI and 38% higher adjusted risks of stroke. These findings may signal potential additional SLE-specific and thrombotic risk factors associated with elevated risk of stroke among SLE patients. Barbhaiya_v10Table_PNG_uploaded.png


Disclosure: M. Barbhaiya, None; C. H. Feldman, None; S. K. Chen, None; H. Guan, None; T. C. Lin, None; M. A. Fischer, None; D. H. Solomon, None; B. M. Everett, None; K. H. Costenbader, UpToDate, 7.

To cite this abstract in AMA style:

Barbhaiya M, Feldman CH, Chen SK, Guan H, Lin TC, Fischer MA, Solomon DH, Everett BM, Costenbader KH. Risk of Cardiovascular Disease Events Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/risk-of-cardiovascular-disease-events-among-patients-with-systemic-lupus-erythematosus-compared-to-those-with-diabetes-mellitus-in-a-nationwide-medicaid-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-cardiovascular-disease-events-among-patients-with-systemic-lupus-erythematosus-compared-to-those-with-diabetes-mellitus-in-a-nationwide-medicaid-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology